...
【24h】

Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations

机译:丙酸氟替卡松在干粉吸入剂配方中的团聚行为

获取原文
获取原文并翻译 | 示例
           

摘要

Due to their small size, the respirable drug particles tend to form agglomerates which prevent flowing and aerosolisation. A carrier is used to be mixed with drug in one hand to facilitate the powder flow during manufacturing, in other hand to help the fluidisation upon patient inhalation. Depending on drug concentration, drug agglomerates can be formed in the mixture. The aim of this work was to study the agglomeration behaviour of fluticasone propionate (FP) within interactive mixtures for inhalation. The agglomerate phenomenon of fluticasone propionate after mixing with different fractions of lactose without fine particles of lactose (smaller than 32 μm) was demonstrated by the optical microscopy observation. A technique measuring the FP size in the mixture was developed, based on laser diffraction method. The FP agglomerate sizes were found to be in a linear correlation with the pore size of the carrier powder bed (R 2 = 0.9382). The latter depends on the particle size distribution of carrier. This founding can explain the role of carrier size in de-agglomeration of drug particles in the mixture. Furthermore, it gives more structural information of interactive mixture for inhalation that can be used in the investigation of aerosolisation mechanism of powder. According to the manufacturing history, different batches of FP show different agglomeration intensities which can be detected by Spraytec?, a new laser diffraction method for measuring aerodynamic size. After mixing with a carrier, Lactohale LH200, the most cohesive batch of FP, generates a lower fine particle fraction. It can be explained by the fact that agglomerates of fluticasone propionate with very large size was detected in the mixtures. By using silica-gel beads as ballmilling agent during the mixing process, the FP agglomerate size decreases accordingly to the quantity of mixing aid. The homogeneity and the aerodynamic performance of the mixtures are improved. The mixing aid based on ball-milling effect could be used to ameliorate the quality of inhalation mixture of cohesive drug, such as fluticasone propionate. However, there is a threshold where an optimal amount of mixing aids should be used. Not only the drug des-aggregation reaches its peak but the increase in drug-carrier adhesion due to high energy input should balance the de-agglomeration capacity of mixing process. This approach provides a potential alternative in DPI formulation processing.
机译:由于其尺寸小,可吸入药物颗粒往往会形成团块,从而阻止流动和雾化。载体用于一方面与药物混合,以在制造过程中促进粉末流动,另一方面有助于在患者吸入时流化。取决于药物浓度,可以在混合物中形成药物附聚物。这项工作的目的是研究氟替卡松丙酸酯(FP)在可吸入的交互式混合物中的团聚行为。通过光学显微镜观察证实丙酸氟替卡松与不同比例的乳糖混合后没有乳糖细颗粒(小于32μm)后的附聚现象。基于激光衍射法,开发了一种测量混合物中FP尺寸的技术。发现FP附聚物的尺寸与载体粉末床的孔径呈线性相关(R 2 = 0.9382)。后者取决于载体的粒度分布。这一发现可以解释载体大小在混合物中药物颗粒解聚中的作用。此外,它提供了更多的吸入性互动混合物的结构信息,可用于研究粉末的雾化机理。根据生产历史,不同批次的FP表现出不同的团聚强度,可通过Spraytec?(一种用于测量空气动力学尺寸的新型激光衍射方法)检测到。与载体混合后,最具内聚力的FP乳杆菌LH200产生较低的细颗粒级分。可以通过以下事实解释:在混合物中检测到丙酸氟替卡松的团聚体非常大。通过在混合过程中使用硅胶珠粒作为球磨剂,FP附聚物的尺寸随混合助剂的量而减小。混合物的均匀性和空气动力学性能得到改善。基于球磨效果的混合助剂可用于改善粘性药物如丙酸氟替卡松的吸入混合物的质量。但是,存在一个阈值,应使用最佳数量的混合助剂。不仅药物解聚集达到其峰值,而且由于高能量输入而引起的药物-载体粘附的增加应平衡混合过程的解聚集能力。这种方法为DPI配方加工提供了潜在的替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号